Societal preference values for advanced melanoma health states in the United Kingdom and Australia.
Beusterien KM., Szabo SM., Kotapati S., Mukherjee J., Hoos A., Hersey P., Middleton MR., Levy AR.
BACKGROUND: No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and unintended toxicities associated with treatment. METHODS: Using standard gamble, utilities were elicited from 140 respondents in the United Kingdom and Australia for 13 health states. RESULTS: Preferences decreased with reduced treatment responsiveness and with increasing toxicity. CONCLUSIONS: These general population utilities can be incorporated into treatment-specific cost-effectiveness evaluations.